Charlottesville, Va. - A federal judge in Virginia on Thursday determined that the 2023 certification requirements for clinicians and pharmacies prescribing the abortion medication mifepristone were unlawful because the Food and Drug Administration failed to justify imposing those limits.
U.S. District Judge Robert Ballou wrote that the agency had repeatedly affirmed the drug's safety and efficacy, but did not explain why the certification rules adopted in 2023 remained necessary. According to Ballou, the FDA did not show that prescribing mifepristone without those conditions would produce an intolerable risk warranting market removal.
The decision was issued in response to a lawsuit brought by three abortion providers in 2023. Ballou said federal law permits him to order the FDA to revisit the regulation, but he indicated he lacked authority to void the rule outright at this stage. He also left open the possibility of addressing separate claims that the rule violated the providers' constitutional rights in a subsequent ruling.
The article's reporting notes that the FDA under the administration of Republican President Donald Trump is conducting a broader review of mifepristone's safety. The medication is used in more than 60% of abortions in the United States.
Meanwhile, Republican-led states and anti-abortion organizations continue to pursue a range of legal measures aimed at restricting access to mifepristone. The judge's ruling resolves one specific regulatory challenge but does not conclude the wider legal and administrative disputes over the drug.
The ruling highlights a pair of procedural paths moving forward: an administrative reconsideration directed to the FDA and potential further litigation concerning constitutional claims from the providers. Those pathways could determine whether the 2023 certification requirements are reimposed, revised, or removed entirely after additional agency analysis or further court decisions.
For stakeholders in health services, pharmacies, and manufacturers, the decision creates an interim legal posture rather than a final change in access or prescribing practices. The court's finding centers on the agency's explanation for the rule rather than a new scientific assessment of the medication's safety or effectiveness.
Summary of legal status: A federal judge ruled the 2023 certification requirements unlawful due to insufficient justification from the FDA, while leaving room for agency reconsideration and for later constitutional rulings. Multiple legal efforts by states and advocacy groups to limit access to mifepristone are ongoing.